Sight Sciences Inc (NASDAQ:SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease.
TearCare is intended to help restore healthy function to diseased meibomian glands by removing obstructions interfering with meibum production and outflow.
The trial met its primary endpoint, and the data reported statistically significant improvements compared to Restasis eye drops for treating dry eye disease.
Also Read: Sight Sciences’ Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use.
These results will be presented in greater detail at the American Academy of Optometry’s annual meeting in October 2023.
The SAHARA trial achieved its primary six-month endpoint, demonstrating the superiority of interventional eyelid procedures enabled by TearCare over Restasis eyedrops in the improvement of tear break-up time, a key measure of aqueous retention, tear stability, and the tear film’s ability to protect the ocular surface.
The SAHARA trial also observed that procedures enabled by TearCare were non-inferior to Restasis eyedrops in Ocular Surface Disease Index, the co-primary six-month endpoint.
Throughout the study, interventional eyelid procedures with TearCare demonstrated clinically and statistically significant improvements at every endpoint and measurement interval.
In the next phase of the SAHARA study, subjects in the Restasis cohort cease using Restasis, receive an interventional eyelid procedure with TearCare, and will be monitored for another six months.
Subjects in the TearCare cohort will receive additional interventional eyelid procedures as necessary over an additional 18 months to measure the durability of the procedural treatment effect.
Final results from SAHARA are expected by 2025.
Price Action: SGHT shares are up 0.91% at $7.78 on the last check Thursday.
